down arrow

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE1000062J1
HKD
483.00
139 (40.41%)

Sep 23

HKG

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
SciClone Pharmaceuticals (Holdings) Ltd.
Livzon Pharmaceutical Group, Inc.
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Ocumension Therapeutics
Shandong Boan Biotechnology Co., Ltd.
Cutia Therapeutics
Lepu Biopharma Co., Ltd.
RemeGen Co., Ltd.
Everest Medicines Ltd.
InnoCare Pharma Ltd.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Why is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ?

1
Weak Long Term Fundamental Strength with a -416.85% CAGR growth in Operating Profits over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -18.01
2
Flat results in Jun 26
  • INVENTORY TURNOVER RATIO(HY) Lowest at 2.21 times
  • PRE-TAX PROFIT(Q) At HKD -535.89 MM has Fallen at -164.55%
  • NET PROFIT(Q) At HKD -376.23 MM has Fallen at -121.4%
3
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -6.72%, its profits have fallen by -41%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
-100.0%
3.15
55.53%
Hang Seng Hong Kong
-5.07%
-0.26
18.70%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
218.50%
EBIT Growth (5y)
-416.85%
EBIT to Interest (avg)
-33.87
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.91
Sales to Capital Employed (avg)
0.15
Tax Ratio
7.36%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
13.76
EV to EBIT
-129.71
EV to EBITDA
-162.72
EV to Capital Employed
154.11
EV to Sales
31.19
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-118.81%
ROE (Latest)
-8.12%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company
NET PROFIT(HY)

Higher at HKD -376.23 MM

ROCE(HY)

Highest at 3.14%

RAW MATERIAL COST(Y)

Fallen by 0.32% (YoY

CASH AND EQV(HY)

Highest at HKD 5,527.95 MM

EPS(Q)

Highest at HKD 1.9

-8What is not working for the Company
INVENTORY TURNOVER RATIO(HY)

Lowest at 2.21 times

PRE-TAX PROFIT(Q)

At HKD -535.89 MM has Fallen at -164.55%

NET PROFIT(Q)

At HKD -376.23 MM has Fallen at -121.4%

DEBTORS TURNOVER RATIO(HY)

Lowest at 5.01 times

Here's what is working for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

EPS
Highest at HKD 1.9
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (HKD)

Cash and Eqv
Highest at HKD 5,527.95 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost
Fallen by 0.32% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation
Highest at HKD 65.82 MM
in the last five periods
MOJO Watch
The expenditure on assets done by the company may have gone into operation

Depreciation (HKD MM)

Depreciation
At HKD 65.82 MM has Grown at 17.28%
period on period (QoQ)
MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (HKD MM)

Here's what is not working for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Pre-Tax Profit
At HKD -535.89 MM has Fallen at -164.55%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (HKD MM)

Net Profit
At HKD -376.23 MM has Fallen at -121.4%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (HKD MM)

Inventory Turnover Ratio
Lowest at 2.21 times and Fallen
In each half year in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio
Lowest at 5.01 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Footer loading